ACAD
29.24
+0.56
+1.95%
AEMD
2.13
-0.2
-8.58%
APRI
1.16
+0.07
+6.42%
ARNA
14.88
-1.31
-8.09%
ATEC
1.88
+0.02
+1.08%
CNAT
5.1
+0.14
+2.82%
CRXM
0.175
+0.00
+0.1719%
CYTX
1.04
0.00
0.00%
DXCM
77.33
-1.35
-1.72%
GNMK
12.75
+0.1
+0.79%
HALO
14.89
+0.06
+0.40%
ILMN
185.28
+2.29
+1.25%
INNV
0.12
+0.01
+9.55%
INO
8.2
+0.12
+1.49%
ISCO
1.15
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
123.87
+0.74
+0.60%
LPTN
2.93
-0.08
-2.66%
MBVX
1.538
+0.068
+4.5918%
MEIP
2.3
+0.14
+6.48%
MNOV
5.54
-0.02
-0.36%
MRTX
3.8
-0.25
-6.17%
MSTX
0.131
-0.007
-5.278%
NBIX
47.35
+0.23
+0.49%
NUVA
76.78
-0.13
-0.17%
ONCS
1.07
-0.07
-6.14%
ONVO
2.76
+0.05
+1.85%
OREX
3.12
+0.03
+0.97%
OTIC
18.75
+1
+5.63%
QDEL
27.38
+0.89
+3.36%
RCPT
231.96
0.00
0.00%
RGLS
0.915
-0.075
-7.576%
RMD
78.44
+0.81
+1.04%
SCIE
0
0.00
0.00%
SPHS
2.06
0.00
0.00%
SRNE
1.85
-0.1
-5.13%
TROV
1.14
-0.16
-12.31%
VICL
2.45
-0.03
-1.21%
VOLC
18
0.00
0.00%
ZGNX
15
0.00
0.00%
ACAD
29.24
+0.56
+1.95%
AEMD
2.13
-0.2
-8.58%
APRI
1.16
+0.07
+6.42%
ARNA
14.88
-1.31
-8.09%
ATEC
1.88
+0.02
+1.08%
CNAT
5.1
+0.14
+2.82%
CRXM
0.175
+0.00
+0.1719%
CYTX
1.04
0.00
0.00%
DXCM
77.33
-1.35
-1.72%
GNMK
12.75
+0.1
+0.79%
HALO
14.89
+0.06
+0.40%
ILMN
185.28
+2.29
+1.25%
INNV
0.12
+0.01
+9.55%
INO
8.2
+0.12
+1.49%
ISCO
1.15
0.00
0.00%
ISIS
57.56
0.00
0.00%
LGND
123.87
+0.74
+0.60%
LPTN
2.93
-0.08
-2.66%
MBVX
1.538
+0.068
+4.5918%
MEIP
2.3
+0.14
+6.48%
MNOV
5.54
-0.02
-0.36%
MRTX
3.8
-0.25
-6.17%
MSTX
0.131
-0.007
-5.278%
NBIX
47.35
+0.23
+0.49%
NUVA
76.78
-0.13
-0.17%
ONCS
1.07
-0.07
-6.14%
ONVO
2.76
+0.05
+1.85%
OREX
3.12
+0.03
+0.97%
OTIC
18.75
+1
+5.63%
QDEL
27.38
+0.89
+3.36%
RCPT
231.96
0.00
0.00%
RGLS
0.915
-0.075
-7.576%
RMD
78.44
+0.81
+1.04%
SCIE
0
0.00
0.00%
SPHS
2.06
0.00
0.00%
SRNE
1.85
-0.1
-5.13%
TROV
1.14
-0.16
-12.31%
VICL
2.45
-0.03
-1.21%
VOLC
18
0.00
0.00%
ZGNX
15
0.00
0.00%
Home » Archive by Category

Xconomy

Woodcock: New Approvals Show FDA Is Adapting to Precision Medicine

May 30, 2017 – 7:57 am

The randomized controlled trial has long been held up as the gold standard for testing new drugs. But the nation’s top drug evaluator, Janet Woodcock, believes they aren’t necessary for all new…

[[Click headline to continue reading.]]

On ASCO’s Eve, Experts Fret Over Backlash to Cancer Combo Frenzy

May 30, 2017 – 3:05 am

When thousands of cancer researchers from around the world gather in Chicago this weekend for the American Society of Clinical Oncology’s annual meeting, drugs that fight tumors by boosting a…

[[Click headline to continue reading.]]

Bio Roundup: Skinny Cuts, Genomic Approvals, Unfrozen FDA & More

May 26, 2017 – 2:55 am

Team Trump unveiled its 2018 federal spending proposal—the so-called “skinny budget”—with health and science in the crosshairs. The NIH is looking at a 22 percent cut and the FDA 31…

[[Click headline to continue reading.]]

Amid Budget Concerns, NIH Preps Beta Test for Precision Medicine Plan

May 25, 2017 – 4:46 am

An ambitious plan to recruit 1 million U.S. volunteers and amass a treasure trove of their health information will start next week with a “beta test” that health officials hope to eventually expand…

[[Click headline to continue reading.]]

Unconventional Partners, Like FDA, Can Drive Adoption of New Tech

May 23, 2017 – 11:00 pm

We’ve heard it time and again. Drug development is too expensive, takes too long, and many drug candidates that show promise in preclinical trials end up failing because testing methods don’t predict…

[[Click headline to continue reading.]]

Gottlieb Says FDA’s “Regulatory Tools” Can Help Fight Opioid Abuse

May 23, 2017 – 3:01 pm

The FDA considers how safe and effective a new drug is before approving it. But for addictive opioid painkillers, which have triggered a massive public health crisis, should the agency also weigh the…

[[Click headline to continue reading.]]

FDA Landmark Nod: Cancer Drug To Match Tumor Genes, Not Tissue Type

May 23, 2017 – 1:23 pm

For many years, doctors and researchers have known that cancers in different parts of the body can share genetic abnormalities. For the first time, the FDA has approved a drug based on those…

[[Click headline to continue reading.]]

ViaCyte Raises $10M, Moves to Human Trial with New Diabetes Product

May 22, 2017 – 9:14 pm

San Diego-based ViaCyte said it is ready to move into human testing with a new product intended for patients with Type 1 diabetes who are at high risk for acute, life-threatening complications from…

[[Click headline to continue reading.]]

Envision the Future: Request Your Invite to Our Napa Summit June 8-9

May 22, 2017 – 6:45 am

We are getting down to the wire—just two and a half weeks until Xconomy’s most unique, up close and personal event of the year: our sixth annual Napa Summit: The Xconomy Retreat on Technology, Jobs,…

[[Click headline to continue reading.]]

Bio Roundup: Termeer Tribute, ASCO Peeks, Califf’s New Gigs & More

May 19, 2017 – 2:35 am

Exhausted by the nonstop drama in Washington, DC? Immerse yourself instead in this week’s biotech headlines. Let’s start with a tribute to a life sciences icon, then we’ll head around the…

[[Click headline to continue reading.]]